The "Therapeutic Psilocybin Act" (HB 1796-FN) establishes a regulated framework for the medical use of psilocybin in clinical settings to treat qualified medical conditions such as treatment-resistant depression, PTSD, and substance use disorders. The bill introduces a new chapter in the law, Chapter 126-XX, which outlines definitions, provisions, and the creation of a psilocybin production establishment licensing board within the Department of Health and Human Services. This board will oversee the licensing of qualified providers who can recommend and administer psilocybin, while also providing legal protections for participants in the program, including cultivators, therapists, and patients. The bill specifies that individuals may recommend, possess, and administer psilocybin in accordance with the new regulations, while federal FDA-approved psilocybin products are exempt from this chapter, except for certain research and treatment funding provisions.

Additionally, the bill establishes a Therapeutic Psilocybin Treatment Fund to support the program financially, funded by licensing fees and appropriations. It includes provisions for data collection to assess the program's efficacy while ensuring patient confidentiality. The Department of Health will oversee compliance, education, and the development of treatment protocols, while a Psilocybin Licensing Board will review applications and recommend medical conditions for psilocybin use. The bill also outlines operational requirements for psilocybin production establishments, including security measures and inventory control, and mandates the creation of an electronic verification system for tracking psilocybin transactions. Overall, HB 1796-FN aims to create a safe and regulated environment for the medical use of psilocybin, while ensuring accountability and transparency in its production and administration.

Statutes affected:
Introduced: 6:12
HB1796 text: 6:12